Status:
TERMINATED
Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib
Lead Sponsor:
University of New Mexico
Conditions:
Cholangiocarcinoma
Eligibility:
All Genders
Brief Summary
Chart Review on Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.
Detailed Description
As above.
Eligibility Criteria
Inclusion
- Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.
Exclusion
- Not specified.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00320918
Start Date
November 1 2005
End Date
October 1 2006
Last Update
January 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of New Mexico
Albuquerque, New Mexico, United States, 87131